{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T21:34:12Z","timestamp":1692999252777},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.ygyno.2005.12.040","type":"journal-article","created":{"date-parts":[[2006,3,4]],"date-time":"2006-03-04T12:24:05Z","timestamp":1141475045000},"page":"468-474","source":"Crossref","is-referenced-by-count":7,"title":["A Phase II trial of oral capecitabine in patients with platinum \u2013 and taxane \u2013 refractory ovarian, fallopian tube, or peritoneal cancer"],"prefix":"10.1016","volume":"102","author":[{"given":"Judith K.","family":"Wolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane C.","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Branham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred D.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neely","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.12.040_bib1","series-title":"Principles and practice of gynecologic oncology","first-page":"895","article-title":"Epithelial ovarian cancer","author":"Ozols","year":"2005"},{"key":"10.1016\/j.ygyno.2005.12.040_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.12.040_bib3","series-title":"Medical oncology: a comprehensive review","first-page":"233","article-title":"Ovarian cancer","author":"Greenberg","year":"2003"},{"key":"10.1016\/j.ygyno.2005.12.040_bib4","first-page":"685","article-title":"Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts","volume":"58","author":"Ishikawa","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.12.040_bib5","first-page":"209","article-title":"New developments in angiogenesis: a major mechanism for tumor growth and target for therapy","volume":"4","author":"Jones","year":"1998","journal-title":"Cancer J."},{"key":"10.1016\/j.ygyno.2005.12.040_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.12.040_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/gyno.1996.0134","article-title":"Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin","volume":"61","author":"Prefontaine","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00000421-199212000-00006","article-title":"5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group","volume":"15","author":"Look","year":"1992","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00000421-199502000-00004","article-title":"A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"Look","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/gyno.1994.1190","article-title":"Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma","volume":"54","author":"Long","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.7-2-120","article-title":"The cancer patient and quality of life","volume":"7","author":"Bottomley","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2005.12.040_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Lui","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib14","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.[online], Accessed April URL: http:\/\/ctep.cancer.gov\/index.html."},{"key":"10.1016\/j.ygyno.2005.12.040_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of a general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","article-title":"The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress","volume":"30A","author":"Portenoy","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.12.040_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clin. Trials"},{"key":"10.1016\/j.ygyno.2005.12.040_bib19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib20","first-page":"62a","article-title":"Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study","volume":"21","author":"Fumoleau","year":"2002","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib21","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contains cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second line treatment for platinum-resistant and platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib24","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.12.040_bib25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.1998.5243","article-title":"Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer","volume":"72","author":"Burger","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/gyno.2000.6089","article-title":"Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma","volume":"81","author":"Sorensen","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2004.09.004","article-title":"Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study","volume":"95","author":"Rothenberg","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib29","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/sj.bjc.6601381","article-title":"A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer","volume":"89","author":"Vasey","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2005.12.040_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.20.1.160","article-title":"Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer","volume":"20","author":"Cartwright","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib31","first-page":"745","article-title":"Quality of life (QoL) in metastatic breast cancer (MBC) patients taking capecitabine","volume":"22","author":"Lago","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.12.040_bib32","unstructured":"Remarks by Dr. von Eschenbach to the Special Populations Networks Cancer Health Disparities Summit Accessed April Available: National Cancer Institute website. www.cancer.gov."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806000230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825806000230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T05:34:06Z","timestamp":1555479246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825806000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0090825806000230"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.12.040","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}